Alexa B. Schrock

Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC).

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

<i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma

Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis

Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer

Tumor Fraction Correlates With Detection of Actionable Variants Across &gt; 23,000 Circulating Tumor DNA Samples

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Clinicopathologic Features and Response to Therapy of<i>NRG1</i>Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing

PD60-01 CASTRATE RESISTANT TMPRSS2: ERG FUSION POSITIVE AND TMPRSS2: ERG WILD TYPE REFRACTORY ACINAR AND NEUROENDOCRINE PROSTATE CANCER DIFFER IN GENOMIC SIGNATURES AND OPPORTUNITIES FOR TARGETED AND IMMUNOTHERAPIES

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures

Identification of <i>NTRK</i> fusions in pediatric mesenchymal tumors

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia